Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5GT1M)

Drug Name

EVANS BLUE Drug Info

Synonyms

tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonatonaphthalen-2-ylidene)hydrazinyl]-3-methylphenyl]-2-methylphenyl]hydrazinylidene]-5-oxonaphthalene-1,3-disulfonate; AC1NUWHB; AC1O426Q; AN-23389; tetrasodium (6E)-4-amino-6-[[4-[4-[(2Z)-2-(8-amino-1-oxo-5,7-disulfonato-2-naphthylidene)hydrazino]-3-methyl-phenyl]-2-methyl-phenyl]hydrazono]-5-oxo-naphthalene-1,3-disulfonate; 6,6-[(3,3'-Dimethyl[1,1'-biphenyl]-4,4'-diyl)bis(azo)bis[4-amino-5-hydroxy-1,3-naphthalenedisulphonic acid]tetrasodium sa

Indication

Disease Entry	ICD 11	Status	REF
Abdominal aortic aneurysm	BD50.4	Approved	[1]

Cross-matching ID

PubChem CID: 9409
ChEBI ID: CHEBI:82467
CAS Number: CAS 314-13-6
TTD Drug ID: DM5GT1M

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Serum albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gadobenate Dimeglumine	DM4VAOG	Schizophrenia	6A20	Approved	[2]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[3]
Oxyphenbutazone	DMPZS7U	Arthritis	FA20	Approved	[4]
Iodipamide	DMXIQYS	Gallbladder disease	DC11.3	Approved	[5]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[6]
Gadofosveset	DM5V9U1	Imaging	QA0B	Approved	[7]
Albumin Human	DM5JTPU	Hypoalbuminemia	5C53.2	Approved	[8]
Bismuth	DMTKU46	Diarrhea	ME05.1	Approved	[9]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[10]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
2	Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
3	Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
4	Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
5	Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
6	Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
7	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
10	ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
11	Clinical pipeline report, company report or official report of Ablynx.